Endometrial Cancer
Study findings on endometrial cancer are outlined in reports from N. Susumu and colleagues
Published in Women's Health Weekly, March 20th, 2008
In this recently published article, scientists in Tokyo, Japan conducted a study "To establish an optimal adjuvant therapy for intermediate- and high-risk endometrial cancer patients, we conducted a multi-center randomized phase III trial of adjuvant pelvic radiation therapy (PRT) versus cyclophosphamide-doxorubicin-cisplatin (CAP) chemotherapy in women with endometrioid adenocarcinoma with deeper than 50% myometrial invasion. Among 385 evaluated patients, 193 patients received PRT and 192 received CAP."
"The PRT group received at least 40 Gy. The CAP group received cyclophosphamide (333 mg/m(2)), doxorubicin (40 mg/m(2)) and cisplatin (50 mg/m(2)) every 4 weeks for 3...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Addiction Medicine
Drinking and aggression among university students often depends on the context - Breast Cancer
Cancer risk slightly higher for women in discontinued hormone treatment trial - Breast Cancer
Drugs like aspirin could reduce breast cancer and help existing sufferers - Breast Cancer
High levels of estrogen associated with breast cancer recurrence - Breast Cancer
Researchers identify new genetic marker for breast cancer - Breast Cancer
WHI follow-up study: Risks of long-term hormone therapy continue to outweigh benefits - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
